Translating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice

Documenti analoghi

• Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis
  di: Lian F. van der Gang, et al.
  Pubblicazione: (2026)
• Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real‐world evidence
  di: Lian F. van der Gang, et al.
  Pubblicazione: (2025)
• Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years
  di: Christopher G. Bunick, et al.
  Pubblicazione: (2025)
• Beyond events per 100 patient‐years: Interpreting 6‐year upadacitinib safety in atopic dermatitis
  di: Anxin Wen
  Pubblicazione: (2025)
• Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials
  di: Jonathan I. Silverberg, et al.
  Pubblicazione: (2026)